Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Methicillin-susceptible (MSSA) is a common cause of bloodstream infection (BSI) in patients with febrile neutropenia, but treatment practices vary, and guidelines are not clear on the optimal regimen.
Methods: We conducted a multicenter retrospective cohort study of MSSA BSI in febrile neutropenia. We divided patients into 3 treatment groups: (1) broad-spectrum beta-lactams (ie, piperacillin-tazobactam, cefepime, meropenem); (2) narrow-spectrum beta-lactams (ie, cefazolin, oxacillin, nafcillin); and (3) combination beta-lactams (ie, both narrow- and broad-spectrum). We used multivariable logistic regression to compare 60-day mortality and bacteremia recurrence while adjusting for potential confounders.
Results: We identified 889 patients with MSSA BSI, 128 of whom had neutropenia at the time of the index culture: median age 56 (interquartile range, 43-65) years and 76 (59%) male. Of those, 56 (44%) received broad-spectrum beta-lactams, 30 (23%) received narrow-spectrum beta-lactams, and 42 (33%) received combination therapy. After adjusting for covariates, including disease severity, combination therapy was associated with a significantly higher odds for 60-day all-cause mortality compared with broad spectrum beta-lactams (adjusted odds ratio [aOR], 3.39; 95% confidence interval [CI], 1.29-8.89; = .013) and compared with narrow spectrum beta-lactams, although the latter was not statistically significant (aOR, 3.30; 95% CI, .80-13.61; = .071).
Conclusions: Use of combination beta-lactam therapy in patients with MSSA BSI and febrile neutropenia is associated with a higher mortality compared with treatment with broad-spectrum beta-lactam after adjusting for potential confounders. Patients in this study who transitioned to narrow-spectrum beta-lactam antibiotics did not have worse clinical outcomes compared with those who continued broad-spectrum beta-lactam therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356691 | PMC |
| http://dx.doi.org/10.1093/ofid/ofac306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients.
Jpn J Clin Oncol
September 2025
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Background: Amrubicin monotherapy has been used in Japan for patients with refractory, relapsed, small cell lung cancer (SCLC). However, the clinical guidelines do not specify a recommended initial dose for elderly patients. This retrospective study aimed to explore the appropriate initial dose of amrubicin for elderly patients with refractory, relapsed SCLC.
View Article and Find Full Text PDF[Retrospective analysis of patients hospitalized for febrile neutropenia - room for improvement?].
Klin Mikrobiol Infekc Lek
June 2025
Clinic of Infectious Diseases, Central Military Hospital, Prague, Czech Republic, e-mail:
Objective: To evaluate the quality of care provided to patients with febrile neutropenia (FN) hospitalized at the Depart-ment of Infectious Diseases, Military University Hospital Prague, as a foundation for improving the management of this condition.
Material And Methods: A retrospective observational analysis of patients diagnosed with the ICD-10 code D70 from 1 January 2015 to 1 June 2023. All evaluated parameters were selected primarily to facilitate the assessment of care quality and compliance with recommended practices.
Early Postoperative Fever in Pediatric Oncology Patients Undergoing Solid Tumor Resection.
J Pediatr Surg
September 2025
Division of Pediatric General and Thoracic Surgery. Cincinnati Children's Hospital Medical Center. 3333 Burnet Avenue, Cincinnati, Ohio 45229; Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address:
Background: Postoperative fever is common following cancer resection and often prompts extensive, costly workups. The purpose of this study was to determine the incidence of and risk factors for postoperative fever in oncology patients, evaluate incidence of true infection, and determine the utility of fever workup.
Methods: Single institution retrospective chart review (2018-2023) identified postoperative oncology patients who developed postoperative fever (≥38.
IMX-SEV-3b mRNA classifier predicts ICU care and 30-day mortality in febrile neutropenic emergency department patients.
Am J Emerg Med
August 2025
Department of Emergency Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, United States of America. Electronic address:
Background: Chemotherapy-associated febrile neutropenia (FN) is a common, life-threatening oncologic emergency. Scores to identify low-risk patients eligible for outpatient treatment, like the Multinational Association for Supportive Care in Cancer (MASCC), Clinical Index of Stable Febrile Neutropenia (CISNE), and quick Sepsis Related Organ Failure Assessment (qSOFA) scores, are infrequently used. New tools are needed to inform risk and enable appropriate management.
View Article and Find Full Text PDFEffects of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis for chemotherapy-induced febrile neutropenia in diffuse large B-cell lymphoma patients receiving the R-CHOP-21 regimen.
Asian Biomed (Res Rev News)
August 2025
Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand.
Background: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) in diffuse large B-cell lymphoma (DLBCL) patients undergoing rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone every 21 d (R-CHOP-21) chemotherapy varies based on physician discretion.
Objectives: The present study aims to investigate the impact of primary G-CSF prophylaxis on febrile neutropenia (FN) and other outcomes in DLBCL patients receiving R-CHOP-21 in real-world practice.
Methods: Medical records of 103 newly diagnosed DLBCL patients, aged 18-80 years, were retrospectively analyzed.